UBS Group’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

UBS Group’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-992	Closed	-$10K	–	11385
2022 Q3	$10K	Hold	992	–	–	﹤0.01%	8488
2022 Q2	$10K	Buy	992 +115	+13%	+$1.16K	﹤0.01%	8043
2022 Q1	$9K	Sell	877 -60	-6%	-$606	﹤0.01%	8586
2021 Q4	$9K	Buy	+937	New	+$9.48K	﹤0.01%	8957

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's PBAXU Position: Q4 2022 in Review

UBS Group sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 992 shares — an estimated $10K sold.

UBS Group first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $10K in Q3 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

UBS Group reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
UBS Group sold 992 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $10K.
UBS Group first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
UBS Group's Phoenix Biotech Acquisition Corp. Unit position peaked at $10K in Q3 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.